Sanofi gets first ever approval within Niemann-Pick as Japan green-lights drug
As the first country in the world, Japan has approved a treatment, Sanofi-developed Xenpozyme, for Niemann-Pick disease type A, also known as acid sphingomyelinase deficiency (ASMD).
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Sanofi is the first and only company in the world to receive an approval for a drug targeting the disease acid sphingomyelinase deficiency (ASMD), Sanofi reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IGM Biosciences and Sanofi enter deal with USD 6bn potential
For subscribers
.jpg&w=384&q=75)
